Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.

Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA; Foundation for the National Institutes of Health β-Cell Project Team.

Diabetes Care. 2016 Sep;39(9):1602-13. doi: 10.2337/dc15-0931. Epub 2016 Jul 12.

2.

Comparison of Handgrip and Leg Extension Strength in Predicting Slow Gait Speed in Older Adults.

Fragala MS, Alley DE, Shardell MD, Harris TB, McLean RR, Kiel DP, Cawthon PM, Dam TT, Ferrucci L, Guralnik JM, Kritchevsky SB, Vassileva MT, Gudnason V, Eiriksdottir G, Koster A, Newman A, Siggeirsdottir K, Satterfield S, Studenski SA, Kenny AM.

J Am Geriatr Soc. 2016 Jan;64(1):144-50. doi: 10.1111/jgs.13871.

3.

Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study.

Sun J, Zhao XQ, Balu N, Hippe DS, Hatsukami TS, Isquith DA, Yamada K, Neradilek MB, Cantón G, Xue Y, Fleg JL, Desvigne-Nickens P, Klimas MT, Padley RJ, Vassileva MT, Wyman BT, Yuan C.

Int J Cardiovasc Imaging. 2015 Jan;31(1):95-103. doi: 10.1007/s10554-014-0532-7. Epub 2014 Sep 13.

4.

Arginine is preferred to glucagon for stimulation testing of β-cell function.

Robertson RP, Raymond RH, Lee DS, Calle RA, Ghosh A, Savage PJ, Shankar SS, Vassileva MT, Weir GC, Fryburg DA; Beta Cell Project Team of the Foundation for the NIH Biomarkers Consortium.

Am J Physiol Endocrinol Metab. 2014 Oct 15;307(8):E720-7. doi: 10.1152/ajpendo.00149.2014. Epub 2014 Aug 26.

5.

Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the Foundation for the National Institute of Health sarcopenia project.

Fragala MS, Dam TT, Barber V, Judge JO, Studenski SA, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Kiel DP, Kritchevsky SB, Shardell MD, Vassileva MT, Kenny AM.

J Gerontol A Biol Sci Med Sci. 2015 Feb;70(2):202-9. doi: 10.1093/gerona/glu110. Epub 2014 Aug 18.

6.

An evidence-based comparison of operational criteria for the presence of sarcopenia.

Dam TT, Peters KW, Fragala M, Cawthon PM, Harris TB, McLean R, Shardell M, Alley DE, Kenny A, Ferrucci L, Guralnik J, Kiel DP, Kritchevsky S, Vassileva MT, Studenski S.

J Gerontol A Biol Sci Med Sci. 2014 May;69(5):584-90. doi: 10.1093/gerona/glu013.

7.

Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project.

McLean RR, Shardell MD, Alley DE, Cawthon PM, Fragala MS, Harris TB, Kenny AM, Peters KW, Ferrucci L, Guralnik JM, Kritchevsky SB, Kiel DP, Vassileva MT, Xue QL, Perera S, Studenski SA, Dam TT.

J Gerontol A Biol Sci Med Sci. 2014 May;69(5):576-83. doi: 10.1093/gerona/glu012.

8.

Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness.

Cawthon PM, Peters KW, Shardell MD, McLean RR, Dam TT, Kenny AM, Fragala MS, Harris TB, Kiel DP, Guralnik JM, Ferrucci L, Kritchevsky SB, Vassileva MT, Studenski SA, Alley DE.

J Gerontol A Biol Sci Med Sci. 2014 May;69(5):567-75. doi: 10.1093/gerona/glu023.

9.

Grip strength cutpoints for the identification of clinically relevant weakness.

Alley DE, Shardell MD, Peters KW, McLean RR, Dam TT, Kenny AM, Fragala MS, Harris TB, Kiel DP, Guralnik JM, Ferrucci L, Kritchevsky SB, Studenski SA, Vassileva MT, Cawthon PM.

J Gerontol A Biol Sci Med Sci. 2014 May;69(5):559-66. doi: 10.1093/gerona/glu011.

10.

The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates.

Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT.

J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58. doi: 10.1093/gerona/glu010.

11.

Atherosclerosis drug development in jeopardy: the need for predictive biomarkers of treatment response.

Fryburg DA, Vassileva MT.

Sci Transl Med. 2011 Mar 2;3(72):72cm6. doi: 10.1126/scitranslmed.3002029.

PMID:
21368220
12.

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.

Wagner JA, Prince M, Wright EC, Ennis MM, Kochan J, Nunez DJ, Schneider B, Wang MD, Chen Y, Ghosh S, Musser BJ, Vassileva MT.

Clin Pharmacol Ther. 2010 May;87(5):539-42. doi: 10.1038/clpt.2009.227. Review.

PMID:
20407460
13.

Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors.

Wagner JA, Wright EC, Ennis MM, Prince M, Kochan J, Nunez DJ, Schneider B, Wang MD, Chen Y, Ghosh S, Musser BJ, Vassileva MT.

Clin Pharmacol Ther. 2009 Dec;86(6):619-25. doi: 10.1038/clpt.2009.88. Epub 2009 Jun 24.

PMID:
19553931
14.

SUMO-1 modification of the Wilms' tumor suppressor WT1.

Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber DA.

Cancer Res. 2004 Nov 1;64(21):7846-51.

15.

SUMO modification of heterogeneous nuclear ribonucleoproteins.

Vassileva MT, Matunis MJ.

Mol Cell Biol. 2004 May;24(9):3623-32.

Supplemental Content

Loading ...
Support Center